EULAR 2023 Lupus Highlights
Rheumnow Podcast
00:00
The Effects of Cyclophosphamide on Proteinuria
Egyptian study looked at cyclophosphamide in a good strong dose monthly for six months and compared that with barisitinib, four milligrams. Now they've continued the study out to 12 months, the reporting the six-month study here and the 12-month study will have renal biopsies, the six- month study did not. At 12 weeks there was significant reduction in proteinuria, 70% for the baris itinib group, 43% for the cyclophosphamonia group. Similarly, the secondary endpoints like C3 and SLEEDI2K was in favor of barisitInib over cycloph phosphamide.
Transcript
Play full episode
